City of Hope is an independent biomedical research and treatment organization for cancer, diabetes and other life-threatening diseases.
Founded in 1913, City of Hope is a leader in bone marrow transplantation and immunotherapy such as CAR T cell therapy. City of Hope’s translational research and personalized treatment protocols advance care throughout the world. Human synthetic insulin, monoclonal antibodies and numerous breakthrough cancer drugs are based on technology developed at the institution. AccessHope™, a subsidiary launched in 2019 serves employers and their health care partners by providing access to City of Hope’s specialized cancer expertise.
A National Cancer Institute-designated comprehensive cancer center and a founding member of the National Comprehensive Cancer Network, City of Hope is ranked among the nation’s “Best Hospitals” in cancer by U.S. News & World Report and received Magnet Recognition from the American Nurses Credentialing Center. Its main campus is located near Los Angeles, with additional locations throughout Southern California and in Arizona.
City of Hope’s commitment to Diversity, Equity and Inclusion
We believe diversity, equity and inclusion is key in serving our mission to provide compassionate patient care, drive innovative discovery, and advance vital education focused on eliminating cancer and diabetes in all of our communities. Our commitment to Diversity, Equity and Inclusion ensures we bring the full range of skills, perspectives, cultural backgrounds and experiences to our work -- and that our teams align with the people we serve in order to build trust and understanding. We are dedicated to fostering a community that embraces diversity - in ideas, backgrounds and perspectives; this is reflected in our work and represented in our people.
Dr. Nadia Carlesso’s research is focused on the mechanisms of leukemogenesis and identification of novel therapeutic approaches in poor prognosis T-ALL. Following recent laboratory discoveries, her group is exploring novel approaches to target the microenvironment/oncogene cooperation driving chemoresistance and relapse in T-ALL leukemia stem cells.
This project is nested on a larger program directed by Dr. Carlesso that focuses on the relationships between the tumor microenvironment, inflammation, and stem cell biology in hematopoietic diseases. Nadia Carlesso, M.D., Ph.D. | City of Hope
Dr. Carlesso is looking for Postdocs to advance the following areas of interest in her laboratory:
- Map the signal transduction oncogenic circuitry in drug-resistant and relapse T-ALL cells.
- Study the microenvironment and leukemic stem cells interactions.
This NIH-NCI funded position is created to expand our recent findings on oncogene cooperation in T-cell leukemogenesis (Rodriguez et al, Leukemia 2020), and on the development of a new in vitro platform to study leukemia/endothelium interactions (Kim et al., Nature Communications 2022).
Candidates with expertise in cell & molecular biology, biochemistry, and in vivo models who are interested in building a career in biomedical research will be most competitive for this position.
Key Responsibilities include:
Basic education, experience and skills required for consideration:
The position will provide considerable opportunities to the postdoctoral fellow for further training and development of additional skills and expertise in a vibrant intellectual and multi-disciplinary scientific environment.
City of Hope is committed to creating a diverse environment and is proud to be an equal opportunity employer. All qualified applicants will receive consideration for employment without regard to race, religion, color, national origin, sex, sexual orientation, gender identity, age, status as a protected veteran, or status as a qualified individual with disability.